Asymchem is a leading CDMO and a partner of choice for many pharmaceutical and biotech companies worldwide by offering integrated solutions across all stages of drug development from discovery through commercialization. With eight R&D and manufacturing sites, 9000+ employees, and an exemplary regulatory record we have the know-how to get things done for you.
Learn how one CDMO is at the forefront of green chemistry, applying its principles to reduce the environmental and human impact of pharmaceutical production.
Spray drying is an established particle engineering technology that offers several advantages over other methods used for improving API bioavailability.
Bikash Chatterjee of Pharmatech Associates discusses the reshoring trend, technologies and advances that could help deliver more manufacturing back to the U.S.
Market estimated to grow at CAGR of 20% from 2021 to 2028 due to an exponential rise in clinical pipeline along with rising number of regulatory approvals.
CDMOs have been some of the biggest winners from COVID contracts and will see benefits for several more years to come. A Q&A with GlobalData’s Peter Shapiro.
Lonza’s Robert Beland discusses best practices for manufacturers to shorten development timelines, as well as some of the capabilities at the CDMO's Tampa site.
From discovery to intermediates, APIs & drug products, a CDMO needs expertise across multiple elements of the pharma process to deliver an integrated experience
To increase small molecule manufacturing capacity for additional scale-up of CleanCap messenger RNA capping technology for vaccine and therapeutic programs.
The chief executive talks industry trends, challenges and what’s in store for PCI Pharma Services as it continues its rapid growth and global expansion strategy
A roundtable discussion about the serialization challenge and why some contract service providers and brand owners are skeptical of each other's readiness
Nabi Biopharmaceuticals has entered into a five-year commercial manufacturing agreement with Diosynth RTP, Inc. for the manufacture of drug substance for NicVAX.